Victoria, British Columbia – March 17, 2020: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia”or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the Company has established U.S. commercial center of operations in Rockville, Maryland. The new site will support Aurinia’s plans for growth as it prepares for the potential approval and launch of voclosporin for lupus nephritis in 2021.
Aurinia’s Rockville site at 77 Upper Rock Circle will initially occupy 30,000 square feet, with potential expansions to 120,000 square feet. The company plans to hire up to 100 employees in the first year and up to 500 employees as the company expands its operations. It is located within the I-270 life sciences and biotech corridor, which is widely recognized as a hotbed of leading innovation and industry talent.
The Maryland Department of Commerce has approved a $2 million conditional loan through Advantage Maryland, formerly the Maryland Economic Development Assistance Authority and Fund (MEDAAF), which will be distributed in $1 million increments as each phase of the project is complete. Additionally, Montgomery County has approved a conditional grant of $350,000 per phase of the project, with the City of Rockville contributing $25,000 for each phase. The company is also eligible for Maryland’s Job Creation Tax Credit.
Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by diseases with a high unmet medical need. The Company is currently developing an investigational drug for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company’s head office is in Victoria, British Columbia, and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.